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Introduction: Despite its high incidence, nerve fiber (axon and myelin) damage after cerebral infarct has not yet
been extensively investigated. The aim of this study was to investigate white matter repair after adipose-derived
mesenchymal stem cell (ADMSC) administration in an experimental model of subcortical stroke. Furthermore, we
aimed to analyze the ADMSC secretome and whether this could be implicated in this repair function.
Methods: An animal model of subcortical ischemic stroke with white matter affectation was induced in rats by
injection of endothelin-1. At 24 hours, 2 × 106 ADMSC were administered intravenously to the treatment group.
Functional evaluation, lesion size, fiber tract integrity, cell death, proliferation, white matter repair markers (Olig-2,
NF, and MBP) and NogoA were all studied after sacrifice (7 days and 28 days). ADMSC migration and implantation
in the brain as well as proteomics analysis and functions of the secretome were also analyzed.
Results: Neither ADMSC migration nor implantation to the brain was observed after ADMSC administration. In
contrast, ADMSC implantation was detected in peripheral organs. The treatment group showed a smaller functional
deficit, smaller lesion area, less cell death, more oligodendrocyte proliferation, more white matter connectivity and
higher amounts of myelin formation. The treated animals also showed higher levels of white matter-associated
markers in the injured area than the control group. Proteomics analysis of the ADMSC secretome identified 2,416
proteins, not all of them previously described to be involved in brain plasticity.
Conclusions: White matter integrity in subcortical stroke is in part restored by ADMSC treatment; this is mediated
by repair molecular factors implicated in axonal sprouting, remyelination and oligodendrogenesis. These findings
are associated with improved functional recovery after stroke.Introduction
White matter injury and the mechanisms of nerve fiber
(axon and myelin) repair have seldom been investigated
in translational stroke research [1, 2], despite the fact
that blood supply disruption also compromises whole
axons and fibers and therefore brain connectivity. Even
though relevant, white matter injury in stroke has not
been extensively studied in the past due to the intrinsic
difficulties associated with animal models; for instance,* Correspondence: mgutierrezfernandez@salud.madrid.org; exuperio.diez@
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creativecommons.org/publicdomain/zero/1.0/the fact that the rodent brain has substantially less white
matter than higher mammals or humans [3, 4]. However,
not only are up to 25 % of ischemic strokes in humans
subcortical [1], but cortical infarcts also produce white
matter injury. The high incidence of such damage moti-
vates the search for an effective therapy that would en-
hance the mechanisms underlying the repair of damaged
nerve fibers after any kind of stroke.
Stem cell therapy has demonstrated its efficacy in cor-
tical stroke and may have a positive effect on subcortical
lesions. In this regard, preclinical studies indicate that
adipose-derived mesenchymal stem cells (ADMSC) are a
promising new therapy for subcortical stroke that could
promote recovery by improving the global brain repair
mechanisms [5–7]. Trophic factor release, paracrine
interactions and immunomodulatory effects have beencess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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in ADMSC therapy [8, 9]. In this regard, stem cells are
known to have paracrine effects on neurogenesis, glio-
genesis, synaptogenesis, vasculogenesis and immunomo-
dulation. However, there is little evidence whether stem
cell administration can promote oligodendrogenesis and
white matter fiber repair when axonal tract integrity has
been compromised.
Therefore, the aim of this study was to investigate the
therapeutic effects (improvement of functional deficits
and enhancement of white matter fiber repair) of the
intravenous administration of ADMSC in rats submitted
to subcortical stroke with white matter injury.
Methods
Ethics statement
The procedure was carried out at our Cerebrovascular
and Neuroscience Research Laboratory, La Paz Univer-
sity Hospital, Madrid, Spain. All experiments were de-
signed to minimize animal suffering in compliance with,
and approved by, our medical school’s Ethical Committee
of La Paz University Hospital for the Care and Use of Ani-
mals in Research according to the Spanish and European
Union rules (86/609/CEE, 2003/65/CE, 2010/63/EU, RD
1201/2005 and RD53/2013).
Animals and surgery
A total of 72 male Sprague–Dawley rats weighing 200–
250 g (Charles River Laboratories, France) were used. In
all animals, the femoral artery was cannulated during
surgery and induction of cerebral ischemia to allow con-
tinuous monitoring of physiological parameters includ-
ing blood glucose levels, blood gases and blood pressure
(Omicron ALTEA Monitor; RGB Medical Devices,
Madrid, Spain). Cranial and body temperature were moni-
tored and maintained at 36.5 ± 0.5 °C. Male Sprague–
Dawley rats (200–250 g) were anesthetized using 3.5 %
isoflurane in 2 L/minute oxygen and given meloxicam
2 mg/kg for analgesia. To provoke white matter injury,
subcortical stroke was induced by injection of 1 μL
endothelin-1 (ET-1; Calbiochem, Germany) (0.25 μg/μL)
with the use of a SYR 5 μL Hamilton syringe (Tecknokroma,
Barcelona, Spain) into the striatum using stereotactic
references (+0.4 mm AP, +3.5 mm L, + 6 mm DV from
bregma) as previously described [10].
After 24 hours, the treatment group received intra-
venously (i.v.) 2 × 106 ADMSC in 1 ml of saline solution
(n = 24) by the tail vein. Dose was determined based on
previous studies [8, 9]. In the control (n = 24) and
sham-operation (n = 24) groups, only saline solution was
i.v. administered via the tail vein. Rats were sacrificed at
24 hours (n = 4 in each group for comparative anatomical
analysis of the lesion in fresh tissue and to analyze
ADMSC distribution), 7 days (n = 10 in each group) or28 days (n = 10 in each group) after treatment for cell
death and proliferation analysis and immunohistochemis-
try, immunofluorescence and Western blot studies.
Cell culture protocol
ADMSC obtained from allogeneic adipose tissue of
Sprague–Dawley rats (250–300 g) were cultured. The adi-
pose tissue was digested with collagenase (Sigma Aldrich,
Madrid, Spain) and incubated at 37 °C in 5 % CO2. On the
third pass, the cell cultures were divided into three groups:
1) 1.0 × 105 ADMSC for characterization, 2) 1.5 × 106
ADMSC for proteomics analysis of the culture super-
natant, and 3) 42 × 106 ADMSC for the treatment of rats.
For characterization, ADMSC were trypsinized and la-
beled with fluorescein isothiocyanate (FITC)-, phycoeryth-
rin (PE)- or Alexa 647-conjugated primary antibodies. The
cells were incubated for 20 minutes at 4 °C in the dark
with the following antibodies: CD90-FITC (AbD Serotec,
Oxford, UK), CD29-PE (AbD Serotec), CD45-PE (AbD
Serotec) and CD11b-PE (AbD Serotec). Matched isotype
controls were purchased from Biolegend (San Diego, CA,
USA). Flow cytometry analysis of CD90+/CD29+/CD45–/
CD11b– cells was performed using a FACScalibur cyt-
ometer and CellQuest Pro software (Becton Dickinson,
Madrid, Spain). For ADMSC treatment, ADMSC with
>95 % viability were administered i.v. The dose, route
and time of administration were based on previously
reported data [9, 11].
Proteomics data analysis
For proteomic analysis of cell culture supernants,
ADMSC were cultured overnight with a free fetal bovine
serum/protein culture medium. After 24 hours, cell super-
natants were collected and the protein content was ana-
lyzed as follows. Proteins were digested using the filter
aided sample preparation (FASP) protocol [12]. Briefly,
samples were dissolved in 50 mM Tris–HCl pH 8.5, 4 %
SDS and 50 mM DTT, boiled for 10 minutes and then
centrifuged. Protein concentration in the supernatant was
measured by the Direct Detect® Spectrometer (Millipore,
Billerica, MA, USA). Approximately 50 μg of protein was
diluted in 8 M urea in 0.1 M Tris–HCl (pH 8.5), and
loaded onto 30 kDa centrifugal filter devices (FASP
Protein Digestion Kit, Expedeon, Knoxville, TN, USA).
The denaturation buffer was replaced by washing three
times with UA. Proteins were later alkylated using 50 mM
iodoacetamide in UA for 20 minutes in the dark, and the
excess alkylation reagents were eliminated by washing
three times with UA and three additional times with 50
mM ammonium bicarbonate. Proteins were digested
overnight at 37 °C with modified trypsin (Promega,
Madison, WI, USA) in 50 mM ammonium bicarbonate
at 40:1 protein to trypsin (w/w) ratio. The resulting
peptides were eluted by centrifugation with 50 mM
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chloride. Trifluoroacetic acid (TFA) was added to a
final concentration of 1 % and the peptides were finally
desalted onto C18 Oasis-HLB cartridges and dried-down
for further analysis.
Peptides were loaded into the LC-MS/MS liquid chro-
matography tandem mass spectrometry system for on-line
desalting onto C18 cartridges and analyzing by LC-MS/
MS using a C-18 reversed phase nano-column (75 μm
internal diameter × 50 cm, 2 μm particle size, Acclaim
PepMap RSLC, 100 C18; Thermo Fisher Scientific,
Waltham, MA, USA) in a continuous acetonitrile gradient
consisting of 0–30 % B in 180 minutes, 50–90 % B in 3
minutes (B = 90 % acetonitrile, 0.5 % formic acid). A flow
rate of 200 nL/minute was used to elute peptides from the
RP nano-column to an emitter nanospray needle for real
time ionization and peptide fragmentation on an Orbitrap
Elite mass spectrometer (Thermo Fisher Scientific). An
enhanced FT-resolution Fourier- Transform spectrum
(resolution = 35,000) followed by the MS/MS spectra from
the most intense 15 parent ions were analyzed along the
chromatographic run. Dynamic exclusion was set at 30
seconds.
For peptide identification, all spectra were analyzed
with Proteome Discoverer (version 1.4.0.29; Thermo
Fisher Scientific) using SEQUEST-HT (Thermo Fisher
Scientific). For database searching on the Uniprot database
containing all sequences from humans (6 March 2013),
parameters were selected as follows: trypsin digestion with
two maximum missed cleavage sites, precursor and frag-
ment mass tolerances of 600 ppm and 0.02 Da, respect-
ively, carbamidomethyl cysteine as fixed modification
and methionine oxidation as dynamic modifications.
Peptide identification was validated using the probabil-
ity ratio method [13] with an additional filtering for
precursor mass tolerance of 10 ppm. False discovery
rate (FDR) was calculated using inverted databases and
the refined method [14]. For the study of the biological
functions of identified proteins, gene onthology ana-
lysis was performed using the GOrilla (Gene Ontology
Enrichment Analysis and Visualization) research tool [15].
Biodistribution analysis
For identification of donor cells, ADMSC were labeled
with DiI (Celltracker CM-DiI, Invitrogen, Barcelona, Spain)
prior to administration and stained with CD90, and pos-
sible migration and implantation were analyzed using im-
munofluorescence. Biodistribution of labeled ADMSC
with DiI 24 hours after i.v. administration was analyzed
using immunofluorescence techniques in both control
and treated animals. Cryosections (10 μm thick) of
brain, kidney, liver, lung and spleen were counterstained
with 4′,6-diamino-2-phenylindole (DAPI) and analyzed
by immunofluorescence staining (n = 4 per group).Functional evaluation
Functional evaluation was performed in all animals by a
blinded observer before surgery and after 1, 3, 7, 14 and
28 days. Motor performance was evaluated using the
beam walking and rotarod tests and Rogers’ functional
scale. The beam walking test measured the ability of rats
to walk along a wooden beam (2.5 × 2.5 × 80 cm).
Scores were assigned as follows: 0, traversed the beam
with no foot slip; 1, traversed with grasping of the lateral
side of the beam; 2, difficulty crawling along the beam
but able to traverse; 3, required >10 seconds to traverse
the beam because of difficulty with walking; 4, unable to
traverse the beam; 5, unable to move the body or any
limb on the beam; and 6, unable to stay on the beam for
>10 seconds [16]. The rotarod test measured the latency
to fall from a rotating cylinder [9]. A variant of Rogers’
functional scale was used to assign scores as follows: 0,
no functional deficit; 1, failure to extend forepaw fully;
2, decreased grip of forelimb while tail gently pulled; 3,
spontaneous movement in all directions, contralateral
circling only if pulled by the tail; 4, circling; 5, walking
only when stimulated; 6, unresponsive to stimulation
with a depressed level of consciousness; and 7, dead
(n = 10 per group) [17].
In vivo magnetic resonance imaging and tractography
Lesion size was analyzed after 1, 7 and 28 days by mag-
netic resonance imaging (MRI) using a 7-Tesla horizontal
bore magnet (Bruker Pharmascan, Ettlingen, Germany)
and T2 maps (RARE 8 T2, 180° flip angle, three averages)
as previously described [9]. The lesion area was expressed
as a percentage of the contralateral hemisphere, after cor-
recting for brain edema. For tractography, diffusion tensor
imaging (DTI) was performed after 1, 7 and 28 days using
a spin-echo single-shot echo-planar imaging pulse se-
quence with the following parameters: TR/TE, 5000/35
ms; signal average, 10; 30 non-collinear diffusion gradients
with diffusion weighting of b = 1,000 s/mm2 and b =
0 s/mm2; and field of view 3.5 × 3.5 cm. A total of
496 slices were evaluated from data acquired in 30
directions. The images were obtained using medInria
(Inria, France), a multi-platform medical image pro-
cessing and visualization software. Zoomed lesion
site three-dimensional diffusion tensor images were
represented using ParaView 4.1.0 software (Los Álamos
National Laboratory, New México, USA) (n = 6 per group,
10 sections per animal) as previously described [10].
Cell death evaluation
Cell death was analyzed in the infarct zone of at least 10
sections from each animal using TUNEL staining (TdT-
FragEL DNA Fragmentation Detection Kit, Oncogene
Research Products, San Diego, CA). The number of
positive cells was counted in a minimum of 10 different
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and dark color using a 40× objective lens and image ana-
lysis software (Image-Pro Plus 4.1, Media Cybernetics,
Rockville, MD, USA) (n = 6 per group, 10 sections per
animal).Cell proliferation analysis
Cell proliferation was analyzed using Ki-67 staining
(1:100, Chemicon, Temecula, CA, USA) after 7 and 28
days, in 10 sections corresponding to the infarct area of
each animal, selected as previously described [18, 19].
The number of positive cells was counted in a minimum
of 10 different random microscopic fields using a 40×
objective lens and Image-Pro Plus 4.1 software (n = 6
per group, 10 sections per animal).
The differentiation of the proliferating cells was ana-
lyzed using co-staining with Ki-67 and NeuN (1:100,
Millipore), Olig-2 (1:400, Millipore) and glial fibrillary
acidic protein (GFAP; 1:400, Chemicon) followed by goat
anti-mouse Alexa Fluor 488 antibody (1:750, Invitrogen).
Images were acquired as a confocal maximum projection
using a Leica TCS-SPE confocal microscope (Leica
Microsystems, Heidelberg, Germany) and the number of
double-positive cells was counted in a minimum of 10
different microscopic fields using a 40× objective lens
and Image-Pro Plus 4.1 software.Immunohistochemical, immunofluorescence and Western
blot analyses
Frozen sections were stained using the CryoMyelin Kit
(Hitobiotech, Wilmington, USA), which allows sensitive
localization and visualization of myelin fibers. The mean
intensity of myelin staining in the region of interest
(ROI) was quantified using a Nikon Eclipse-Ti inverted
microscope and NIS-elements software. The lesion area
was studied in detail using immunofluorescence and
Western blot analyses. The white matter-associated anti-
bodies used were neurofilament (NF; 1:100, Dako, Glostrup,
Denmark), neurite outgrowth inhibitor (NogoA; 1:100,
Abcam, Cambridge, UK), myelin basic protein (MBP;
1:100, Abcam) and oligodendrocyte (Olig-2; 1:500,
Millipore) followed by goat anti-mouse Alexa Fluor 488
and anti-rabbit Alexa Fluor 594 (1:750, Invitrogen). For
Western blot analysis, the units were normalized based on
Β-actine (1:400, Sigma-Aldrich). To quantify the expres-
sion of white matter-associated markers, the mean fluor-
escence intensity was evaluated in a minimum of 10
different microscopic fields using a 40× objective lens.
The experiments, images and quantification of the
samples were performed on the same day using the
same microscope configurations, by blinded observers,
to eliminate bias due to background normalization
(four animals, four sections per animal).Statistical analysis
Results were expressed as mean ± standard error of the
mean (SEM). Data were compared using the Kruskal-
Wallis test followed by the Mann–Whitney test. Values
of p < 0.05 were considered as statistically significant. The
analysis was performed using statistical SPSS 16 and
GraphPad software (GraphPad Software Inc, CA, USA).
Results
ADMSC characterization, migration and implantation in
the injured brain area
ADMSC showed typical fibroblast-like cell morphology
and their phenotype was CD90+/CD29+/CD45–/CD11b–
(Fig. 1a).
DiI and CD90 co-labeled cells were not observed in
the control group. Migration and implantation in the
brain were not observed on immunofluorescence images
of the injured brain area after intravenous administration
of DiI and CD90 co-labeled cells. However, DiI and
CD90 co-labeled cells were observed in peripheral or-
gans such as the liver, lung and spleen (Fig. 1b).
Effect of ADMSC treatment on functional recovery
To assess the potential of ADMSC administration to im-
prove functional recovery after subcortical stroke, motor
function was assessed before surgery and after 1, 3, 7, 14
and 28 days using the walking beam, rotarod and Roger’s
test. There were significant differences in motor deficit
scores between the treatment and control group; the
walking beam test performance was significantly better
in the treatment group than in the control group after 3
days (p < 0.01), 14 days (p < 0.05) and 28 days (p < 0.05).
The Rotarod test was significantly better in the ADMSC
treatment group than in the control group after 1 day
(p < 0.01) and 28 days (p < 0.05). The Rogers’ func-
tional scale score was significantly better in the treat-
ment group than in the control group after 7 and 28
days (both p < 0.05) (Fig. 2).
Effect of ADMSC treatment on lesion size and tract
connectivity
MRI analysis showed no significant difference in infarct
size between the treatment and control groups after 1
and 7 days. However, the infarct size was significantly
smaller in the treatment group than in the control
group after 28 days (0.12 ± 0.01 vs. 0.6 ± 0.26, p < 0.05)
(Fig. 3).
Myelin was stained using the CryoMyelin Kit to iden-
tify the area of white matter injury in the subcortical in-
farct. The mean intensity of staining in the ROI was
evaluated in the treatment and control groups, with
white indicating absence of myelin and black indicating
the presence of myelinated axons. There was higher in-
tensity (indicating absence of myelin) in the control
Fig. 1 Characterization and biodistribution of ADMSC. a ADMSC characterization by flow cytometry. Rat ADMSC were labeled with CD29, CD90,
CD11b, and CD45 and analyzed by flow cytometry. Of the ADMSC population, 95 % expressed CD29 and CD90. Additionally, these cells lacked
expression (5 % positive) of CD11b, CD45. b Migration and implantation in the brain and peripheral organs (liver, lung and spleen) of DiI- and
CD90-labelled cells at 24 hours after treatment. AD-MSC adipose-derived mesenchymal stem cells, DAPI 4′,6-diamino-2-phenylindole, FITC
fluorescein isothiocyanate, PE phycoerythrin
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ment group (155.71 mean intensity ± 21.23) (Fig. 3).
DTI tractography data showed similar results in axial
diffusivity (120.35 ± 12.45 µm2/s and 126.78 ± 18.34;
p > 0.05) in both the control and treated groups, re-
spectively, at 7 days. However, compared with the con-
trol rats, 28 days after treatment the ADMSC-treatedFig. 2 Improved functional outcome after ADMSC administration in subcortica
14 and 28 days (p < 0.05). Rotarod test (middle) showed significant differences
days (p < 0.05). The ADMSC group also showed significantly better scores com
Data are shown as mean ± SEM; *p < 0.05, **p < 0.005; n = 10 animals per grrats showed significantly improved axial diffusivity
(127.98 ± 9.21 and 162.99 ± 13.65 µm2/s, respectively;
p < 0.05) compared to controls. These results suggest
that there was a significant improvement in white matter
thickness (width, breadth, depth) and restoration of tract
connectivity in the ADMSC-treated animals compared
with controls at 28 days.l stroke. Beam walking test performance (left) was improved at 3 (p < 0.01),
between the ADMSC group and control animals at 1 (p < 0.01) and 28
pared to controls at 7 and 28 days (p < 0.05) on the Roger’s test (right).
oup. AD-MSC adipose-derived mesenchymal stem cells
Fig. 3 ADMSC treatment reduced infarct size and increased fiber tract and myelin integrity after subcortical white matter damage. a
Morphological study by CryoMyelin staining identified the zone of the lesion as an area of white matter injury located in the subcortical zone,
showing restored myelinated axons in the ADMSC-treated animals. b Quantification of mean ROI intensity of the CryoMyelin staining. Stroked line
indicates ROI; yellow line indicates a representative longitudinal profile of pixel intensity. c Comparative image analysis T2-weighted MRI and
tractography at 1, 7 and 28 days showed a progressive reduction in white matter infarct size in controls and treated animals. Detail of tractography
image in the lesion is given below showing augmented connectivity of fiber tracts in ADMSC-treated animals at 28 days. d Quantitative analysis of MRI
images showed that ADMSC therapy reduced lesion size at 28 days compared to the controls (p < 0.05). Data are shown as mean ± SEM; *p < 0.05;
n = 6 animals, 10 sections each per group. ADMSC adipose-derived mesenchymal stem cells, d days, MRI magnetic resonance image, ROI region
of interest
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cell proliferation
Cell death was analyzed on frozen sections by TUNEL
staining after 7 and 28 days. After 7 days, no significant
differences were found in TUNEL-positive cells in both
the control group (718.5 ± 146.3 cells) and the treatment
group (460.33 ± 120.5 cells). After 28 days, there were
significantly fewer TUNEL-positive cells in the ischemic
area in the treatment group than in the control group
(24.5 ± 1.73 vs. 56.0 ± 3.46 cells, p < 0.05) (Fig. 4a).Quantitative analysis of proliferative cells was per-
formed using Ki-67 labeling after 7 and 28 days. After 7
days, there were no significant differences in proliferative
cells in both the treatment group (83.5 ± 34.65 cells)
and the control group (19.5 ± 7.78 cells) (Fig. 4b). After
28 days, the number of Ki-67-positive cells was signifi-
cantly higher in the treatment group than in the control
group (13 ± 1.15 vs. 3 ± 1.15 cells, p < 0.05). The
proportions of proliferating cell types observed by co-
staining with Ki-67 were not significantly different
Fig. 4 ADMSC administration led to a cell death reduction and improved brain proliferation activity. a Quantitative analysis of cell death by
TUNEL technique showed a significant reduction in TUNEL-positive cells after ADMSC therapy compared to the control group (p < 0.05). b At 28
days, Ki-67 staining shows a significant increase in the number of proliferating cells in ADMSC-treated animals compared to the control group
(p < 0.05). c At 28 days after treatment, Ki-67 co-labeling with NeuN, GFAP, and Olig-2 showed different cell type proliferation including
oligodendrocytes. Data are shown as mean ± SEM; scale bars = 20 μm; n = 6 animals, 10 sections each per group. ADMSC adipose-derived
mesenchymal stem cells, DAPI 4′,6-diamino-2-phenylindole, GFAP glial fibrillary acid protein, NeuN neuronal nuclei, Olig-2 oligodendrocite
transcription factor 2
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3 % vs. 16 ± 5 %, Olig-2: 27 ± 3 % vs. 26 ± 4 %; GFAP,
33 ± 15 % vs. 27 ± 13 %) (Fig. 4c). However, although
there were no significant differences between the pro-
portions of the cell lines, higher levels of each cell type
were found in the ADMSC-treated group.
Effect of ADMSC treatment on white matter-associated
marker expression
After finding that ADMSC administration had a benefi-
cial effect on functional outcome, we investigatedwhether the functional outcome was related to the levels
of white matter-associated markers. Western blot ana-
lysis found that the level of NF (a marker of axonal
sprouting) was not significantly different between the
treatment and control groups after 7 days. However, the
NF level was significantly higher in the treatment group
than in the control group after 28 days (4.27 ± 1.26 vs.
1.00 ± 0.69 Arbitrary Units (AU), p < 0.001). The MBP
level was significantly higher in the treatment group
than in the control group after 7 days (1.09 ± 0.23 vs.
0.63 ± 0.18 AU, p < 0.05) and 28 days (0.80 ± 0.11 vs.
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cantly higher in the treatment group than in the con-
trol group after 28 days (1.08 ± 0.10 vs. 0.32 ± 0.08 AU,
p < 0.05). The NogoA level was not significantly differ-
ent between the treatment and control groups after 7
days (0.68 ± 0.35 vs. 0.67 ± 0.17 AU, p > 0.05), and
tended to be lower in the treatment group than in the
control group after 28 days (0.55 ± 0.35 vs. 1.16 ± 0.34
AU, p > 0.05) (Fig. 5). The NF immunofluorescence in-
tensity was significantly higher in the treatment group
than in the control group after 28 days (10,020.28 ±Fig. 5 White matter-associated markers are enhanced in striatum after ADM
and b immunofluorescence quantification of white matter repair-associated m
c Western blot and d Western blot quantification showed increased levels of
(p < 0.05), as well as augmented levels of Olig-2, NF (p < 0.05) and a trend to
bars = 20 μm; *p < 0.05; n = 4 animals, 4 sections each per group. ADMSC ad
NF neurofilament, Nogo-A neurite outgrowth inhibitor, Olig-2 oligodendrocite1,231.19 vs. 3,536.21 ± 643.2 average fluorescence in-
tensity, p < 0.05). The MBP immunofluorescence inten-
sity was significantly higher in the treatment group than
in the control group after 7 days (5,714.61 ± 529.59 vs.
3,529.97 ± 1,222.40 AU, p < 0.05) and 28 days (6,920.39
± 1,134.27 vs. 3,736.34 ± 324.50 AU, p < 0.05). The
Olig-2 immunofluorescence intensity was significantly
higher in the treatment group than in the control
group after 28 days (2,439.00 ± 231.12 vs. 353.40 ±
111.12 AU, p < 0.05). The NogoA immunofluorescence
intensity tended to be lower in the treatment groupSC therapy in subcortical stroke model. a Immunofluorescence images
arkers (NF, MBP, Olig-2 and NogoA) at 7 and 28 days after treatment.
MBP in the treated group compared to controls at both 7 and 28 days
decreased levels of NogoA. Data are shown as mean ± SEM; scale
ipose-derived mesenchymal stem cells, d days, MBP myelin basic protein,
transcription factor 2
Fig. 6 Proteomics analysis of ADMSC secretome reveals multiple biological functions. a Gene onthology (GO) analysis of the 2,416 proteins
identified by Orbitrap proteomic study. Bars indicate the number of proteins from the total associated with each biological function. b Trophic
factor-related proteins identified in the proteomic analysis; PSM: peptide- spectrum matches c GO functional clustering of proteins associated
with binding function and d other biological processes
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767.32 vs. 2,423.88 ± 876.70 AU, p > 0.05).
Proteomics analysis of the ADMSC in vitro secretome
Proteomics analysis of the secretome of cell cultures
identified 2,416 proteins in the cell supernatants that are
implicated into different cell functions (Fig. 6a), such as
protein binding (carbohydrate binding, antigen binding,
ion binding, sulfur compound binding, and lipid binding),
metabolic processes, single and multicellular organism
processes, development, endodermal cell differentiation,
skin and cartilage morphogenesis, immune system pro-
cesses, cellular organization and biogenesis, response to
stimulus and biological adhesion processes . All functions
in detail are shown in Fig. 6c and d. Full proteomic data is
given in Additional file 1. Interestingly, some of these pro-
teins are also implicated in growth factor activity, such as
several trophic factors and receptors known to be also in-
volved in brain plasticity. Some of these trophic factors
are shown in Fig. 6b.
Discussion
The results of this study showed that ADMSC adminis-
tration plays a major role in improving the repair of
white matter fiber tracts in an experimental model of
subcortical stroke. We found that the treated group had
better functional recovery and smaller lesion size than
the control group. In addition, animals which received
ADMSC treatment showed significantly higher number
of proliferating cells (including oligodendrocyte progeni-
tors) and significantly less cell death at the lesion region
than animals in the control group. Analysis of fiber tract
integrity by tractography and CryoMyelin staining
showed that white tract thickness had been recovered in
the treatment group. The treated group with ADMSC
also had higher levels of white matter-associated
markers (NF, MBP and Olig-2) than the control group,
suggesting that ADMSC administration induced repair
of white matter fiber tracts.
Up to 25 % of ischemic strokes in humans are subcor-
tical or lacunar, which are confined to white matter re-
gions such as the striatum and internal capsule [1]. The
high frequency of damage to these areas in stroke pa-
tients has motivated the search for useful experimental
animal models of subcortical stroke with white matter
affectation, as well as effective therapies to enhance the
mechanisms underlying repair of damaged white matter
(axon and myelin). In this regard, endothelin (one of the
most potent known vasoconstrictors) was considered the
best candidate to induce this injury with white matter
affectation [10, 20, 21].
ADMSC administration is considered an appropriate
therapeutic strategy because ADMSC enhance the natural
repair processes of the brain after injury. However, themechanisms underlying these repair processes are still un-
known. Our proteomics analysis identified thousands of
proteins, many of them not previously associated with
stem cell properties or stroke repair; for instance, we
identified a number of proteins such as hepatoma-
derived growth factor, latent-transforming growth factor
beta, and connective tissue growth factor. Other pro-
teins previously implicated in stem cell therapy function
such as transforming growth factor-beta, fibroblast
growth factor, vascular endothelial growth factor or
brain-derived neurotrophic factor were also identified.
Moreover, gene onthology analysis identified a number
of protein functions not previously associated with stem
cell therapy function in stroke recovery. In this regard,
protein binding (carbohydrate binding, antigen binding,
ion binding, sulfur compound binding, lipid binding),
metabolic processes, single and multicelular organism
processes, development, endodermal cell differentiation,
skin and cartilage morphogenesis, immune system pro-
cesses, cellular organization and biogenesis, response to
stimulus and biological adhesion processes were highly
represented. Interestingly, growth factor activity was
not the main represented function in the cell secretome,
indicating that other functions are also relevant. Our
findings suggest that the release of the identified pro-
teins by the administered ADMSC could contribute to
improve functional recovery when allocated to periph-
eral organs (spleen, lung and liver). However, futures
studies will be needed in order to understand the com-
plex molecular mechanisms involved in stem cell
therapy-mediated stroke recovery.
Various tests have been used to evaluate motor func-
tion following brain injury. Previous studies by our
group have demonstrated improvement in the functional
outcome after ADMSC administration in another experi-
mental animal model of cerebral ischemia [9]. The
present study showed that functional recovery at 28 days
was significantly improved after ADMSC administration
than in the control group after subcortical ischemic
stroke.
In the present study, MRI studies showed a signifi-
cantly smaller infarct size in the treated group than in
the control group after 7 and 28 days. Our results are
consistent with previous studies that reported a reduc-
tion in infarct size after ADMSC administration in an-
other animal model of cerebral ischemia [9]. This
reduction in infarct size could be related to the in-
creased tract thickness and axonal projections observed
by tractography and CryoMyelin staining. These results
agree with previously reported findings that neural pro-
genitor cell treatment in an animal model of cortical is-
chemia results in white matter reorganization shown by
fiber tracking maps derived from DTI and by histological
staining [22].
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TUNEL-positive cells in the ischemic area peaked after 7
days in both treated and control groups. However, the
treated group had less focal damage at 28 days, with sig-
nificantly lower numbers of TUNEL-positive cells than
in the control group. These results are consistent with
those of previously reported studies, which found that
ADMSC administration inhibited cell death in the in-
farct area [5, 9].
The central nervous system continuously generates
new cells in several specific regions of the adult mam-
malian brain, and this proliferation has been shown to
be enhanced by cell therapy. Ki-67 staining showed large
numbers of proliferative cells after 7 days in both the
treatment and control groups. In this regard, our results
are consistent with a previous study [23]. Furthermore,
there was greater cell proliferation after 28 days in the
treated group than in the control group. These results
provide clear evidence that ADMSC administration
induces significant cell proliferation at 28 days after
subcortical stroke. Furthermore, analysis of the prolif-
erating cell lines showed similar proportions of co-
staining with Ki-67 and NeuN, Olig-2 and GFAP in the
treatment and control groups, indicating that almost
half of the proliferating cells in both groups were white
matter-associated cells (neurons and oligodendro-
cytes). These findings indicate genesis of new astro-
cytes and neurons as well as oligodendrocyte progenitors
and immature oligodendrocytes after cerebral ischemia.
Although the effects of ADMSC on neurogenesis, gliogen-
esis, synaptogenesis and vasculogenesis after stroke have
already been described, the ability of ADMSC to pro-
mote oligodendrogenesis after subcortical stroke is a
novel finding.
It is known that some brain repair mechanisms are
quickly activated after cortical ischemia [24], but there is
little information available regarding brain repair mecha-
nisms after subcortical white matter stroke. To increase
our understanding of these mechanisms, we investigated
the levels of white matter-associated markers (NF, MBP,
Olig-2 and NogoA) in both the treatment and control
groups. NF levels, a marker of axonal sprouting, were
not significantly different between the treated and con-
trol groups after 7 days, suggesting that the extent of
white matter injury was similar in these groups during
the acute phase. However, NF levels were higher in the
group treated with ADMSC after 28 days, which could
be explained by enhancement of axonal sprouting after
ADMSC administration. In addition to axonal growth,
restoration of the myelin sheath is important for the
repair of white matter. Furthermore, Olig-2 levels were
significantly higher in the treated group than in the con-
trol group after 28 days. These results support the con-
cept that ADMSC enhance oligodendrogenesis torestore their loss due to ischemic injury. Our findings
are supported by those of a recent in vitro study, which
found that mesenchymal stem cell-conditioned medium
promoted oligodendroglial cell maturation [25]. In
addition to formation of mature oligodendrocytes, re-
pair of the myelin sheath by oligodendrocytes is essen-
tial for achieving propagation of nerve impulses along
axons [26]. The present study analyzed the MBP level as
a marker of myelination. There were significantly higher
levels of MBP in the treatment group compared to the
control group after 7 and 28 days. These higher levels of
MBP and Olig-2 are consistent with the increased pro-
liferation observed for all phases of oligodendrocyte
progenitors. Our results suggest that ADMSC adminis-
tration increases oligodendrogenesis after white matter
stroke.
Finally, among the myelin-associated proteins, NogoA,
myelin-associated glycoprotein and oligodendrocyte
myelin-associated protein all share a single receptor
complex [27]. The present study did not find a differ-
ence in the NogoA level between the treated and con-
trol groups after 7 days. However, the NogoA level
tended to be lower in the treatment group than in the
control group after 28 days. These results may indicate
that ADMSC administration can enhance axonal
growth and plasticity by reducing the level of NogoA.
In addition to indicating axonal sprouting, these find-
ings are in accordance with the tractography and Cryo-
Myelin stain findings that suggest restoration of white
tract connectivity in the area of ischemia induced by
injection of ET-1.
Conclusions
The findings of this study support the concept that
ADMSC play an important role in enhancing some of
the major mechanisms of remyelination. ADMSC ad-
ministration resulted in a smaller lesion size and less cell
death, as well as increased cell proliferation including
oligodendrocyte progenitors, and higher levels of white
matter-associated markers (NF, MBP and Olig-2) and
restoration of white tract connectivity in the infarct area.
All these processes may help to explain the improvement
in functional outcome after ADMSC administration.
Therapies that enhance remyelination may help to pre-
vent the functional deficits resulting from those strokes
affecting the white matter.Additional file
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